CN Bio has formed a long-term strategic partnership with Pharmaron to integrate and advance Organ-on-a-Chip (OOC) technologies across global drug discovery and development platforms.

Under the agreement, Pharmaron will validate CN Bio’s PhysioMimix system for use in disease modelling, toxicity testing, and ADME studies. The companies plan to embed the platform within Pharmaron’s R&D operations worldwide, with the aim of developing new OOC applications to meet growing demand for human-relevant, animal-free testing models.

CN Bio said the collaboration would allow it to install PhysioMimix instruments at multiple Pharmaron sites, expanding the reach of its OOC technologies and accelerating development timelines through joint innovation.

“This partnership allows us to combine global scale with deep scientific expertise, helping drive more effective solutions to market faster,” said Paul Brooks, CEO of CN Bio.

The announcement follows recent regulatory shifts, including the FDA’s move to phase out mandatory animal testing for some drugs, creating new urgency for viable preclinical alternatives. CN Bio’s chief scientific officer Tomasz Kostrzewski noted the technology is ‘well suited’ to fill emerging gaps, particularly in areas such as immune-mediated organ damage.

Pharmaron’s CSO Hua Yang said OOC systems have strong potential to improve translational insight at the preclinical stage, calling the collaboration a step forward in enhancing development success rates and service quality.